; (B) provide information on where the vaccine can be obtained; and (C) create multilingual and culturally appropriate messaging to disseminate scientific and evidence-based information related to vaccines. (2) Details of campaigns Information disseminated by an entity receiving a grant under this section shall— (A) be based on available scientific evidence; (B) increase awareness and knowledge of COVID–19, including countering stigma associated with COVID–19; (C) improve information on the availability of COVID–19 vaccines, including countering misinformation and disinformation with evidence-based scientific rebuttals; and (D) improve awareness and knowledge of coverage of COVID–19 vaccines. (d) Prioritization In awarding grants under this section, the Secretary shall give priority to eligible entities in either urban or rural communities (or a combination of urban and rural communities) that serve vulnerable populations, including communities of color, which may include low-income, uninsured, and medically underserved individuals or populations with historically low rates of receiving vaccines. (e) Timing The Secretary shall awards the grants under this section not later than 30 days after the earlier of— (1) the date on which the Food and Drug Administration licenses a COVID–19 vaccine under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ); or (2) the date on which a manufacturer begins to distribute a COVID–19 vaccine to public or private entities pursuant to an emergency use authorization under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 ). (f) Evaluation The Secretary shall— (1) conduct qualitative assessments regarding the campaign under this section